News >

CARD Trial Establishes Cabazitaxel as a Third-Line Standard in mCRPC

Caroline Seymour
Published: Thursday, Jan 09, 2020

Celestia S. Higano, MD, FACP, professor, Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center

Celestia S. Higano, MD, FACP

Cabazitaxel (Jevtana) has become a third-line standard of care in men with metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase III CARD trial, said Celestia S. Higano, MD, FACP.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication